DYADIC INTERNATIONAL INC (DYAI): Nasdaq/NYSE listing notice — Dyadic receives Nasdaq deficiency notice for continued listing rule non-compliance

DYADIC INTERNATIONAL INC

Received notice on March 27, 2026 for non-compliance with Nasdaq Listing Rule 5550(b) requiring $2.5M equity, $35M market value, or $500K net income.
Company has 45 days to submit a compliance plan; cure period up to 180 days if plan accepted.
Also remains non-compliant with minimum bid price rule (need $1.00) until June 17, 2026.
Failure to cure either deficiency could lead to delisting of common stock from Nasdaq.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

DYADIC INTERNATIONAL INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

March 27, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is out of compliance with the technical minimum requirements for continued listing under Nasdaq Listing Rule 5550(b) (the “Continued Listing Requirement”). The Continued Listing Requirement requires the Company to maintain at least one of the following: $2.5 million in stockholders’ equity; $35 million in market value of listed securities; or $500,000

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

DYADIC INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001493152-26-013405

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.